Full Press Release Details
Lexington, MA.,, Sept. 19, 2017 (GLOBE NEWSWIRE) --Dr. Robert Clarke, CEO and President ofPulmatrix, Inc.(Nasdaq:PULM),interviews on the Uptick Network Stock Day Podcast with host Everett Jolly. During the first half of the interview, Dr. Clarke discusses the partnership with Vecturato develop Pulmatrix’s drug candidate, PUR0200, for chronic obstructive pulmonary disease (COPD) for the U.S. market and highlights that Vectura and/or its partners will be responsible for all future development costs for the U.S. With a deal structure that includes a technology transfer fee and mid-teen percent revenue share Dr. Clarke explains the program’s trial phases, that both companies benefit from the partnership around a multi-billion dollar US product and future potential combinations, and when the program is expected to finalize in the future.
Dr. Clarke shares that the most advanced compound from Pulmatrix’s recent in-license from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc., PUR1800, will be developed as an anti-inflammatory for the treatment of acute exacerbations of COPD and the potential positive effects and blockbuster size opportunity of the PUR1800 compound treatment in comparison to the competitive steroid medication already on the market. Furthermore, Dr. Clarke discusses the status of Pulmatrix’s PUR1900 inhaled antifungal program to treat fungal infections in the airways of patients with severe asthma and cystic fibrosis and the expected benefits of PUR1900 over currently available oral therapies.
To listen to the full interview pleaseclick hereor the following link:https://upticknewswire.com/interview-ceo-dr-robert-clarke-of-pulmatrix-inc-nasdaq-pulm
About PulmatrixPulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF) and severe asthma, and PUR1800, a narrow spectrum kinase inhibitor for patients with COPD. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for COPD. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
FORWARD-LOOKING STATEMENTSCertain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 10, 2017, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required bylaw.